Environment: PROD

What We Support

Cookies for Kids' Cancer™ provides annual research grants to seven of the nation's leading pediatric cancer centers to advance the development of new, improved, & less toxic treatments for children battling cancer.

Why We Exist - The Realities of Childhood Cancer

  • Cancer is the number one cause of death by disease of children in the U.S.
  • The National Cancer Institute's (NCI) federal budget was $4.6 billion. Of that, breast cancer received 12%, prostate cancer received 7%, and all 12 major groups of pediatric cancers combined received less than 3%.
  • Two-thirds of pediatric cancer patients will develop long-term side effects, many life-threatening -- a result of the treatments that "cured" them.
  • Only four of the 12 most common types of childhood cancers have average survival rates over 80%.
  • 13,500 children in the U.S. are diagnosed with cancer each year.
  • There is ONE THING that can truly change the facts of childhood cancers forever -- FUNDING for research to find new, improved therapies.

Learn more about the realities of childhood cancer.

Our Partner Centers:

  • Children's Hospital of Philadelphia
  • Dana-Farber Cancer Institute
  • Fred Hutchinson Cancer Research Center
  • Memorial Sloan Kettering Cancer Center
  • St. Jude Children's Research Hospital
  • Texas Children's Cancer Center
  • University of California San Francisco
As of 2013, a portion of funds raised are also used to MATCH, dollar for dollar, the federal allowance per child enrolled in the Children's Oncology Group's Phase I & Pilot Consortium.

Medical Advisory Board

Fund direction is overseen by a Medical Advisory Board, consisting of some of the nation's leading pediatric oncology professionals. The Board helps us identify critical needs and promising developments, so we can bring safer, more effective treatments to children as quickly as possible. Your donations can be directed to a specific cancer or fund. If you donate to our General Fund, the Board will guide fund granting through a peer review process.

John Maris, MD

Children's Hospital of Philadelphia

Susan Blaney, MD

Texas Children's Cancer Center

Scott Armstrong, MD

Dana-Farber Cancer Institute

Kim Kramer, MD

Memorial Sloan Kettering Cancer Center

Michael LaQuaglia, MD

Memorial Sloan Kettering Cancer Center

Alberto Pappo, MD

St. Jude Children's Research Hospital

Mignon Loh, MD

University of California, San Francisco

Douglas S. Hawkins, MD

Seattle Children’s Hospital

Statement of Need

Pediatric oncology has come a long way in the last several decades. Cure rates have improved overall and advances in research have provided seminal insights into the cancer problem in general. However, this cure rate has come at significant cost. First, the intensity of therapies used to has increased substantially, so the majority of childhood cancer patients have significant long-term complications.

Clearly, cure is not enough. Of equal urgency, several cancers, especially the solid malignancies, have not shown improvement in cure rates and current treatments are at their maximal intensity. Indeed, several cancers have seen no significant progress in over a decade and childhood cancer remains the number one cause of death in children from disease (accidents claim the most lives).

Cancer research is responsible for the achievements to date, with pediatric oncologist showing the world how to perform meaningful clinical research that influences clinical care. However, the next generation of research that will lead to meaningful differences is quite different, and will rely on a detailed understanding of cancer biology with a newly facile was to translate discoveries to the clinic. It is often said that it takes a decade to develop a new cancer drug.

Clearly, this is not acceptable. We have dramatically decreased the timeline to get new therapies to children with refractory cancer, and this new translational molecular oncology will be the pathway to the next revolution in cure rates. However, this type of research is resource intensive. Philanthropic investment will provide the essential catalyst to make more discoveries and move them to improving cure rates as quickly as possible, and a partnership between researchers and "investors" in this mission will be critical to expand in order to make a difference now.

John M. Maris, MD, Children's Hospital of Philadelphia